ACRO Forecasts Radiologist Surplus

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 1
Volume 5
Issue 1

OAK BROOK, Ill--Young physicians seeking careers in radiation on-cology may have severely limited employment opportunities in the foreseeable future, according to the American College of Radiation Oncology (ACRO). The College forecasts that up to 1,000 radiation oncologists will be either underemployed or unemployed shortly after the year 2000.

OAK BROOK, Ill--Young physicians seeking careers in radiationon-cology may have severely limited employment opportunities inthe foreseeable future, according to the American College of RadiationOncology (ACRO). The College forecasts that up to 1,000 radiationoncologists will be either underemployed or unemployed shortlyafter the year 2000.

The College's Personnel Needs Assessment Committee found thatapproximately 800 new radiation oncologists will enter the jobmarket in the next 5 years while fewer than 200 existing radiationoncologists will leave the workforce during the same period.

Quality of Training Affected

The Committee anticipates that the annual average caseload isexpected to remain between 210 and 216 patients through the year2004. A surplus of radiation oncologists may decrease patientcaseload at large medical centers and limit the number of patientsavailable for resident training, thereby adversely affecting thequality of training available to radiation oncology residents.

"The word needs to get out," said ACRO president WilliamD. Bloomer. "Unlike medical subspecialists who can fall backon general internal medicine if their specialty practice falters,radiation oncologists have no fall-back position without majorre-training."

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content